| | 16 October 2023 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Director Dealings
Alliance Pharma plc (AIM: APH), the international healthcare group, has been notified that on 13th October 2023 each of Peter Butterfield, Chief Executive Officer of Alliance, and Andrew Franklin, Chief Financial Officer, have exercised share options pursuant to the Company's Long Term Incentive Plan as set out below.
Peter Butterfield has exercised options over 98,342 ordinary shares of 1 pence each in the Company ("Ordinary Shares"). These options were granted in 2019 at nil cost and were set to expire on 5 December 2023. Following this exercise, 74,343 Ordinary Shares were sold at a price of £0.39016 per share, with an element of the proceeds being applied to satisfy the nominal value exercise price of the options, costs and tax liabilities. In accordance with the Company's share retention policy, following this transaction, Mr Butterfield has a beneficial interest in 466,103 Ordinary Shares and 1,818,750 vested but unexercised share options.
Andrew Franklin has exercised options over 55,592 Ordinary Shares. These options were granted in 2019 at nil cost and were set to expire on 5 December 2023. Following this exercise, 42,053 Ordinary Shares were sold at a price of £0.39016 per share, with an element of the proceeds being applied to satisfy the nominal value exercise price of the options, costs and tax liabilities. In accordance with the Company's share retention policy, following this transaction, Mr Franklin has a beneficial interest in 192,911 Ordinary Shares and 1,450,501 vested but unexercised share options.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Peter Butterfield | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | ALLIANCE PHARMA PLC | |
| b) | Legal Entity Identifier | 213800RYIWZA4Q5WPZ13 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 1 pence each
GB0031030819 | |
| b) | Nature of the transaction | a) Exercise of options b) Sale of Ordinary Shares | |
| c) | Currency | GBP | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| a) 1 pence (nominal value) b) £0.39016
| a) 98,342 b) 74,343 | ||
|
|
| ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total | a) 98,342 options over Ordinary Shares, at nil cost save par value per share (being 1 pence per share and an aggregate of £983.42).
b) 74,343 Ordinary Shares, sold at an average price of £0.39016 per Ordinary Share, totalling £29,005.66
| |
| f) | Date of the transaction(s) | 13 October 2023 | |
| g) | Place of the transaction | London Stock Exchange, AIM | |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Andrew Franklin | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | ALLIANCE PHARMA PLC | |
| b) | Legal Entity Identifier | 213800RYIWZA4Q5WPZ13 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 1 pence each
GB0031030819 | |
| b) | Nature of the transaction | c) Exercise of options d) Sale of Ordinary Shares | |
| c) | Currency | GBP | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) 1 pence (nominal value) d) £0.39016
| a) 55,592 b) 42,053 | ||
|
|
| ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total | a) 55,592 options over Ordinary Shares, at nil cost save par value per share (being 1 pence per share and an aggregate of £555.92)
b) 42,053 Ordinary Shares, sold at an average price of £0.39016 pence per Ordinary Share, totalling £16,407.40
| |
| f) | Date of the transaction(s) | 13 October 2023 | |
| g) | Place of the transaction | London Stock Exchange, AIM | |
For further information:
| Alliance Pharma plc | + 44 (0)1249 466966 |
| Head of Investor Relations: Cora McCallum | + 44 (0)1249 705168 |
| | |
| | |
| Buchanan | + 44 (0)20 7466 5000 |
| Mark Court / Sophie Wills / Hannah Ratcliff | |
| | |
| | |
| Numis Securities Limited (Nominated Adviser and Joint Broker) | + 44 (0)20 7260 1000 |
| Freddie Barnfield / Duncan Monteith / Sher Shah | |
| | |
| Investec Bank plc (Joint Broker) | + 44 (0)20 7597 5970 |
| Patrick Robb / Maria Gomez de Olea | |
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.